苦碟子注射液辅助治疗早期糖尿病肾病临床疗效的系统评价

Systematic Review of the Therapeutic Efficacy of Kudiezi Injection on the Adjunctive Treatment of Diabetic Nephropathy

目的系统评价苦碟子注射液辅助治疗糖尿病肾病的临床疗效。方法计算机检索Pub Med、CNKI、VIP、CBM、万方等数据库公开发表的苦碟子注射液辅助治疗糖尿病肾病的随机对照研究,检索年限均为1990年1月—2014年7月,提取资料后对纳入研究进行文献质量评价,采用Rev Man 5.2统计软件对同质性结果进行合并分析。结果共纳入10项研究,合计1 138例患者。Meta分析结果显示,苦碟子注射液能显著降低糖尿病肾病患者的尿微量白蛋白排泄率[SMD=--.49,95%CI(-1.97,-1.01),P<0.01]和血肌酐[SMD=-0.59,95%CI(-0.80,-0.38),P<0.01],显著提高临床疗效[RR=6.34,95%CI(4.27,9.41),P<0.01],但对血糖无影响[SMD=-0.18,95%CI(-0.44,-0.08),P>0.01]。结论苦碟子注射液能显著提高糖尿病肾病的临床疗效。

OBJECTIVE To evaluate therapeutic efficacy of Kudiezi injection on the adjunctive treatment of diabetic nephropathy. METHODS Retrieved from PubMed, CNKI, VIP, CBM and Wangfang databas, randomized controlled trials（RCT） about Kudiezi injection in the adjunctive treatment of diabetic nephropathy were included from January 1990 to July 2014 and comprehensively evaluated. The homogeneity test and combined test were performed by Rev Man 5.2 software. RESULTS Ten RCTs were included, invovling 1 138 patients. Meta-analysis showed that Kudiezi injection could significantly decrease the value of urinary albumin excretion rate （UAER）[SMD=-l.49, 95%CI（-1.97, -1.01）, P〈0.01] and serum creatinine[SMD=-0.59, 95%CI（-0.80, -0.38）, P〈0.01], so could significantly improve the rate of clinical efficiency[RR=6.34, 95%CI（4.27, 9.41）, P〈0.01], but could not decrease the value of blood glucose[SMD=-0.18, 95%CI（-0.44, -0.08）, F〉0.01]. CONCLUSION Kudiezi injection has clinical curative effect on the adjunctive treatment of diabetic nephropathy.